Published Papers & Misc - TANAKA Shinji

Division display  161 - 180 of about 233 ／  All the affair displays >>

  1. Miura T, Ban D, Koyama T, Kudo A, Ochiai T, Irie T, Nakamura N, Tanaka S, Arii S.. Severe postoperative hemorrhage caused by antibody-mediated coagulation factor deficiencies: report of two cases. Surg. Today. 2014.05; 44 (5): 976-981. ( PubMed, DOI )

  2. Katsuta E, Tanaka S, Mogushi K, Matsumura S, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanaka H, Tanabe M, Arii S.. Age-related clinicopathologic and molecular features of patients receiving curative hepatectomy for hepatocellular carcinoma. Am. J. Surg.. 2014.05; ( PubMed, DOI )

  3. Kudo A, Igari T, Kumagai J, Tanaka S, Ban D, Noguchi N, Irie T, Nakamura N, Arii S.. A simple index to predict liver functional reserve after hepatectomy. Hepatogastroenterology. 2014.04; 61 712-716.

  4. Ogawa K, Tanaka S, Matsumura S, Murakata A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanabe M, Arii S.. EpCAM-targeted therapy for human hepatocellular carcinoma. Ann. Surg. Oncol.. 2014.04; 21 (4): 1314-1322. ( PubMed, DOI )

  5. Kudo A, Mogushi K, Takayama T, Matsumura S, Ban D, Irie T, Ochiai T, Nakamura N, Tanaka H, Anzai N, Sakamoto M, Tanaka S, Arii S.. Mitochondrial metabolism in the noncancerous liver determine the occurrence of hepatocellular carcinoma: a prospective study. J. Gastroenterol.. 2014.03; 49 (3): 502-510. ( PubMed, DOI )

  6. Yasui Y, Kudo A, Kurosaki M, Matsuda S, Muraoka M, Tamaki N, Suzuki S, Hosokawa T, Ueda K, Matsunaga K, Nakanishi H, Tsuchiya K, Itakura J, Takahashi Y, Tanaka S, Asahina Y, Enomoto N, Arii S, Izumi N.. Reduced organic anion transporter expression is a risk factor for hepatocellular carcinoma in chronic hepatitis C patients: a propensity score matching study. Oncology. 2014.01; 86 (1): 53-62. ( PubMed, DOI )

  7. Kano Y, Konno M, Kawamoto K, Tamari K, Hayashi K, Fukusumi T, Satoh T, Tanaka S, Ogawa K, Mori M, Doki Y, Ishii H. Novel drug discovery system for cancer stem cells in human squamous cell carcinoma of the esophagus. Oncology Reports. 2014; 86 (1): 53-62.

  8. Sato K, Tanaka S, Mitsunori Y, Mogushi K, Yasen M, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanaka H, Arii S.. Contrast-enhanced intraoperative ultrasonography for vascular imaging of hepatocellular carcinoma; clinical and biological significance. Hepatology. 2013; 57 (4): 1436-1447. ( PubMed, DOI )

  9. Muramatsu S, Tanaka S, Mogushi K, Adikrisna R, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanaka H, Nakayama K, Tanaka H, Yamaoka S, Arii S. . Muramatsu S, Tanaka S, Mogushi K, Adikrisna R, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanaka H, Nakayama K, Tanaka H, Yamaoka S, Arii S. Visualization of stem cell features in human hepatocellular carcinoma enlightened in vivo significance of tumor-host interaction and clinical implication. Hepatology, 58:218-228, 2013 Hepatology. 2013; 58 218 -228.

  10. Adikrisna R, Tanaka S, Muramatsu S, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Yamaoka S, Arii S. Adikrisna R, Tanaka S, Muramatsu S, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Yamaoka S, Arii S. Identification of pancreatic cancer stem cells and selective toxicity of chemotherapeutic agents. Gastroenterology, 143:234-245, 2012 Gastroenterology, 143:234-245, 2012 . 2012;

  11. Matsumura S, Imoto I, Kozaki K, Matsui T, Muramatsu T, Furuta M, Tanaka S, Sakamoto M, Arii S, Inazawa J. . Matsumura S, Imoto I, Kozaki K, Matsui T, Muramatsu T, Furuta M, Tanaka S, Sakamoto M, Arii S, Inazawa J. Integrative array-based approach identifies MZB1 as a frequently methylated putative tumor-suppressor in hepatocellular carcinoma. Clinical Cancer Research, 18:3541-3551, 2012 Clinical Cancer Research, 18:3541-3551, 2012. 2012;

  12. Tanaka S, Arii S.. Tanaka S, Arii S. Molecular targeted therapy in hepatocellular carcinoma. Seminars in Oncology, 39:486-92, 2012 Seminars in Oncology, 39:486-92, 2012. 2012;

  13. Tanaka S, Mogushi K, Yasen M, Ban D, Noguchi N, Kudo A, Nakamura N, Tanaka H, Yamamoto M, Kokudo N, Takayama T, Kawasaki S, Sakamoto M, Arii S. . Tanaka S, Mogushi K, Yasen M, Ban D, Noguchi N, Kudo A, Nakamura N, Tanaka H, Yamamoto M, Kokudo N, Takayama T, Kawasaki S, Sakamoto M, Arii S. Oxidative stress pathways in non-cancerous human liver tissue to predict hepatocellular carcinoma recurrence; a prospective multi-center study. Hepatology, 54:1273-1281, 2011 Hepatology, 54:1273-1281, 2011. 2011;

  14. Murakata A, Tanaka S, Mogushi K, Yasen M, Noguchi N, Irie T, Kudo A, Nakamura N, Tanaka H, Arii S. Murakata A, Tanaka S, Mogushi K, Yasen M, Noguchi N, Irie T, Kudo A, Nakamura N, Tanaka H, Arii S. Gene expression signature of the gross morphology in hepatocellular carcinoma. Annals of Surgery, 253:94-100, 2011 Annals of Surgery, 253:94-100, 2011. 2011;

  15. Aihara A, Tanaka S, Yasen M, Matsumura S, Mitsunori Y, Murakata A, Noguchi N, Kudo A, Nakamura N, Ito K, Arii S. Aihara A, Tanaka S, Yasen M, Matsumura S, Mitsunori Y, Murakata A, Noguchi N, Kudo A, Nakamura N, Ito K, Arii S. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. Journal of Hepatology, 52:63-71, 2010 Journal of Hepatology, 52:63-71, 2010. 2010;

  16. Tanaka S, Arii S.. Tanaka S, Arii S. Molecularly targeted therapy for hepatocellular carcinoma. Cancer Science, 100:1-8, 2009 Cancer Science, 100:1-8, 2009. 2009;

  17. Tanaka S, Arii S, Yasen M, Mogusi K, Su N-T, Zhao C, Imoto I, Eishi Y, Inazawa J, Miki Y, Tanaka H.. Tanaka S, Arii S, Yasen M, Mogusi K, Su N-T, Zhao C, Imoto I, Eishi Y, Inazawa J, Miki Y, Tanaka H. Aurora kinase B is a predictive factor for aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. British Journal of Surgery, 95:611-619, 2008 British Journal of Surgery, 95:611-619, 2008. 2008;

  18. Tanaka S, Noguchi N, Ochiai T, Kudo A, Nakamura N, Ito K, Kawamura T, Teramoto K, Arii S. . Tanaka S, Noguchi N, Ochiai T, Kudo A, Nakamura N, Ito K, Kawamura T, Teramoto K, Arii S. Outcomes and recurrence of initially resection of hepatocellular carcinoma meeting Milan criteria: Rationale for partial hepatectomy as first strategy. Journal of the American College of Surgeons, 204:1-6, 2007 Journal of the American College of Surgeons, 204:1-6, 2007. 2007;

  19. Tanaka S, Pero SC, Taguchi K, Shimada M, Mori M, Krag DN, Arii S. Tanaka S, Pero SC, Taguchi K, Shimada M, Mori M, Krag DN, Arii S. Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis. Journal of the National Cancer Institute, 98:491-498, 2006 Journal of the National Cancer Institute, 98:491-498, 2006. 2006;

  20. Harimoto N, Taketomi A, Kitagawa D, Kuroda Y, Itoh S, Gion T, Tanaka S, Shirabe K, Shimada M, Maehara Y. Harimoto N, Taketomi A, Kitagawa D, Kuroda Y, Itoh S, Gion T, Tanaka S, Shirabe K, Shimada M, Maehara Y. The newly established human hepatocyte cell line: application for the bioartificial liver. Journal of Hepatology, 42:557-64, 2005 Journal of Hepatology, 42:557-64, 2005. 2005;

< PREV - NEXT >

To the head of this page.▲